161 related articles for article (PubMed ID: 17927520)
1. Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application.
Smith KD; Shao MY; Posner MC; Weichselbaum RR
Future Oncol; 2007 Oct; 3(5):545-56. PubMed ID: 17927520
[TBL] [Abstract][Full Text] [Related]
2. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
4. Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity.
Veerapong J; Bickenbach KA; Shao MY; Smith KD; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2007 Sep; 67(17):8301-6. PubMed ID: 17804745
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
6. Rethinking herpes simplex virus: the way to oncolytic agents.
Campadelli-Fiume G; De Giovanni C; Gatta V; Nanni P; Lollini PL; Menotti L
Rev Med Virol; 2011 Jul; 21(4):213-26. PubMed ID: 21626603
[TBL] [Abstract][Full Text] [Related]
7. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
8. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
Mahller YY; Rangwala F; Ratner N; Cripe TP
Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
[TBL] [Abstract][Full Text] [Related]
9. Bovine herpesvirus type 1 as a novel oncolytic virus.
Rodrigues R; Cuddington B; Mossman K
Cancer Gene Ther; 2010 May; 17(5):344-55. PubMed ID: 19893594
[TBL] [Abstract][Full Text] [Related]
10. [Progess on research of herpes simplex virus type 1 mutants for cancer therapy].
Long Y; Mi Y; Li Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Dec; 25(6):1446-9. PubMed ID: 19166228
[TBL] [Abstract][Full Text] [Related]
11. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1.
Smith KD; Mezhir JJ; Bickenbach K; Veerapong J; Charron J; Posner MC; Roizman B; Weichselbaum RR
J Virol; 2006 Feb; 80(3):1110-20. PubMed ID: 16414988
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
13. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
16. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells.
Wakimoto H; Johnson PR; Knipe DM; Chiocca EA
Gene Ther; 2003 Jun; 10(11):983-90. PubMed ID: 12756419
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography of herpes simplex virus 1 oncolysis.
Kuruppu D; Brownell AL; Zhu A; Yu M; Wang X; Kulu Y; Fuchs BC; Kawasaki H; Tanabe KK
Cancer Res; 2007 Apr; 67(7):3295-300. PubMed ID: 17409438
[TBL] [Abstract][Full Text] [Related]
18. Advance in herpes simplex viruses for cancer therapy.
Liu S; Dai M; You L; Zhao Y
Sci China Life Sci; 2013 Apr; 56(4):298-305. PubMed ID: 23564184
[TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
Liu TC; Wakimoto H; Martuza RL; Rabkin SD
Clin Cancer Res; 2007 Oct; 13(19):5897-902. PubMed ID: 17908985
[TBL] [Abstract][Full Text] [Related]
20. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
Fu X; Tao L; Cai R; Prigge J; Zhang X
Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
